Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON

Rofagha, Soraya; Bhisitkul, Robert B.; Boyer, David S.; Sadda, Srinivas R; Zhang, Kang

doi:10.1016/j.ophtha.2013.03.046

Cited by 911 publications

(770 citation statements)

References 16 publications

Supporting

Mentioning

707

Contrasting

Unclassified

Order By: Relevance

“…Patient expectations are influenced by fellow-eye status, the longevity of the course of treatment and the consequential burden of multiple attendances, investigations and invasive treatment delivery. 5,6 Furthermore, there is also the emerging issue of when to continue, discontinue or change treatment from one n-AMD therapy to another.…”

Section: Introductionmentioning

confidence: 99%

Defining response to anti-VEGF therapies in neovascular AMD

Amoaku

Chakravarthy

Gale

et al. 2015

Eye

272

227

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Defining response to anti-VEGF therapies in neovascular AMD

Amoaku

Chakravarthy

Gale

et al. 2015

Eye

272

227

View full text Add to dashboard Cite

“…Loss of 410 letters occurred in 32% of the eyes that continued treatment for 46.5 years, and GA at the centre of the fovea was the most common cause of visual loss, accounting for 37% of the total. 29 Comparing their methods and results with similar reports such as the SEVEN-UP and the UK EMR Users Group studies, 30,31 they stated more injections were given in their study and better VA results were achieved. The percentage of atrophy involving the foveal centre in the Gillies study was much lower than that recorded in others, for example, in the SEVEN-UP study.…”

Section: Retrospective Studiesmentioning

confidence: 85%

Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents

Gemenetzi

Lotery

Patel

2016

Eye

104

View full text Add to dashboard Cite

Anti-vascular endothelial growth factor (VEGF) intravitreal agents are the only successful treatment for wet age-related macular degeneration (AMD). However, there are emerging signals that anti-VEGF treatment can potentially increase development of geographic atrophy (GA). Histopathologic, animal, and clinical studies support this hypothesis although direct proof of a relationship between GA and use of anti-VEGF agents in neovascular AMD is not yet established. This review presents current evidence supporting an association between anti-VEGF therapy and progression of geographic atrophy. The need of exploring alternative methods of treating AMD is indirectly but clearly emphasized.

show abstract

“…The efficacy of ranibizumab for the treatment of neovascular AMD was shown in several clinical trials 2,3,9,12,16,17 . The MARINA clinical trial compared ranibizumab against placebo in 716 patients 3 .…”

Section: Discussionmentioning

confidence: 99%

Risk for Low Visual Acuity After 1 and 2 Years of Treatment With Ranibizumab or Bevacizumab for Patients With Neovascular Age-Related Macular Degeneration

Westborg

Albrecht

Rosso

2017

Retina

View full text Add to dashboard Cite

Purpose: To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice. Methods: Data from the Swedish Macula Register on the treatment received by 3,912 patients during 2011 to 2014 is reported. Patients' characteristics at the first visit, visual acuity, number of injections, and reason for terminating the treatment if applicable are discussed. Furthermore, the risk of having poor vision (visual acuity under 60 Early Treatment Diabetes Retinopathy Study letters or approximately 20/60 Snellen) is calculated for the treated eye after 1 year and 2 years. Results: The treatment outcome depends on the visual acuity at the first visit. For patients with visual acuity more than 60 letters, the risk of having a visual acuity lower than 60 letters after 1 year or 2 years of treatment is approximately 20%. However, for patients with low visual acuity at diagnosis (fewer than 60 letters), the risk is approximately 60%. The risk of having a visual acuity lower than 60 letters does not depend on the choice of treatment drug. Conclusion: Treatment with anti-vascular endothelial growth factor intravitreal injections mainly maintains the visual acuity level, and only approximately 20% and 40% of the patients required vision rehabilitation after 1 year and 2 years, respectively.

show abstract

Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON

Cited by 911 publications

References 16 publications

Defining response to anti-VEGF therapies in neovascular AMD

Defining response to anti-VEGF therapies in neovascular AMD

Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents

Risk for Low Visual Acuity After 1 and 2 Years of Treatment With Ranibizumab or Bevacizumab for Patients With Neovascular Age-Related Macular Degeneration

Contact Info

Product

Resources

About